S'abonner

Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis - 17/08/16

Doi : 10.1016/S1473-3099(16)30055-X 
Gaurav Kwatra, MSc a, b, , Marianne C Cunnington, PhD c, , Elizabeth Merrall, PhD d, Peter V Adrian, PhD a, b, Margaret Ip, ProfMD e, Keith P Klugman, ProfMD a, g, h, Wing Hung Tam, ProfMD f, Shabir A Madhi, ProfMD a, b, i,
a Medical Research Council, Respiratory and Meningeal Pathogen Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa 
b National Research Foundation, Vaccine Preventable Diseases, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa 
c Real World Evidence, GlaxoSmithKline, London, UK 
d Biostatistics and Statistical Programming, GlaxoSmithKline, Amsterdam, Netherlands 
e Department of Microbiology, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China 
f Department of Obstetrics and Gynaecology, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China 
g Department of Global Health, Emory University, Atlanta, GA, USA 
h Pneumonia Program, Bill & Melinda Gates Foundation, Washington, DC, USA 
i National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa 

* Correspondence to: Prof Shabir A Madhi, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, Gauteng 2131, South Africa Correspondence to: Prof Shabir A Madhi National Institute for Communicable Diseases National Health Laboratory Service Johannesburg Gauteng 2131 South Africa

Summary

Background

The most important risk factor for early-onset (babies younger than 7 days) invasive group B streptococcal disease is rectovaginal colonisation of the mother at delivery. We aimed to assess whether differences in colonisation drive regional differences in the incidence of early-onset invasive disease.

Methods

We did a systematic review of maternal group B streptococcus colonisation studies by searching MEDLINE, Embase, Pascal Biomed, WHOLIS, and African Index Medicus databases for studies published between January, 1997, and March 31, 2015, that reported the prevalence of group B streptococcus colonisation in pregnant women. We also reviewed reference lists of selected studies and contacted experts to identify additional studies. Prospective studies in which swabs were collected from pregnant women according to US Centers for Disease Control and Prevention guidelines that used selective culture methods were included in the analyses. We calculated mean prevalence estimates (with 95% CIs) of maternal colonisation across studies, by WHO region. We assessed heterogeneity using the I2 statistic and the Cochran Q test.

Findings

221 full-text articles were assessed, of which 78 studies that included 73 791 pregnant women across 37 countries met prespecified inclusion criteria. The estimated mean prevalence of rectovaginal group B streptococcus colonisation was 17·9% (95% CI 16·2–19·7) overall and was highest in Africa (22·4, 18·1–26·7) followed by the Americas (19·7, 16·7–22·7) and Europe (19·0, 16·1–22·0). Studies from southeast Asia had the lowest estimated mean prevalence (11·1%, 95% CI 6·8–15·3). Significant heterogeneity was noted across and within regions (all p≤0·005). Differences in the timing of specimen collection in pregnancy, selective culture methods, and study sample size did not explain the heterogeneity.

Interpretation

The country and regional heterogeneity in maternal group B streptococcus colonisation is unlikely to completely explain geographical variation in early-onset invasive disease incidence. The contribution of sociodemographic, clinical risk factor, and population differences in natural immunity need further investigation to understand these regional differences in group B streptococcus maternal colonisation and early-onset disease.

Funding

None.

Le texte complet de cet article est disponible en PDF.

Plan


© 2016  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 16 - N° 9

P. 1076-1084 - septembre 2016 Retour au numéro
Article précédent Article précédent
  • Assessment of global guidelines for preventive chemotherapy against schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study
  • Nathan C Lo, Ying-Si Lai, Dimitrios-Alexios Karagiannis-Voules, Isaac I Bogoch, Jean T Coulibaly, Eran Bendavid, Jürg Utzinger, Penelope Vounatsou, Jason R Andrews
| Article suivant Article suivant
  • Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review
  • Laura Folgori, Julia Bielicki, Beatriz Ruiz, Mark A Turner, John S Bradley, Daniel K Benjamin, Theoklis E Zaoutis, Irja Lutsar, Carlo Giaquinto, Paolo Rossi, Mike Sharland

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.